{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-210825","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.886987+00:00","generated_at":"2026-05-14T21:56:42.449021+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MBX Biosciences Q1 net loss $23.5M; Phase 3 canvuparatide start on track for Q3 2026","bullets":["Cash, equivalents and marketable securities of $440M; expected to fund operations into 2029.","R&D expenses $18.5M (down from $22.4M YoY); G&A expenses $8.8M (up from $4.1M YoY).","Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism to initiate in Q3 2026 after successful FDA End-of-Phase 2 meeting.","Appointed Mark Soued as Chief Commercial Officer; he led Alnylam's US amyloidosis business and AMVUTTRA launch.","Obesity Day on May 11 to present initial blinded MBX 4291 Phase 1 data; amycretin prodrug nomination expected this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-210825","json":"https://secwatch.observer/filing/0001193125-26-210825.json","markdown":"https://secwatch.observer/filing/0001193125-26-210825.md","text":"https://secwatch.observer/filing/0001193125-26-210825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526210825/0001193125-26-210825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526210825/mbx-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:56:42.449021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c21c161a93e44c6ae2b8b07599203405169d38b6","claim":"MBX Biosciences, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was $23.5 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2026, was $23.5 million compared to a net loss of $23.9 million for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526210825/0001193125-26-210825-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2026, was $23.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}